Who is sponsoring NCT00267176?

NCT00267176 is sponsored by Novartis Pharmaceuticals.

What condition does NCT00267176 study?

NCT00267176 studies Osteoarthritis, Controlled Hypertension.

What is the status of NCT00267176?

NCT00267176 is currently COMPLETED.

Last reviewed 2017-02-03 · How we verify

A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to Ibuprofen 600 mg Three Times a Day in Osteoarthritis Patients With Controlled Hypertension

NCT00267176 Phase 4 COMPLETED

This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 4
Status	COMPLETED
Enrolment	1020
Start date	2005-11

Conditions

Osteoarthritis
Controlled Hypertension

Interventions

lumiracoxib

Primary outcomes

Assessment of the 24-hour systolic BP profile of lumiracoxib 100 mg o.d. in comparison to ibuprofen 600 mg t.i.d. after 4 weeks of treatment.

Countries

United States, Germany